New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 16, 2012
07:14 EDTDGXQuest Diagnostics raises cost savings initiative $100M, to $600M
Consistent with management's previously announced intent to deliver greater cost savings in a shorter time frame, the company plans to announce it has now increased its cost savings commitment related to its Invigorate initiative by $100M. It will indicate that it now expects to exit 2014 with run-rate savings of $600M, increased from the previously announced goal of $500M. Management also is now committing to deliver $500M of savings in 2014.
News For DGX From The Last 14 Days
Check below for free stories on DGX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
13:01 EDTDGXQuest Diagnostics management to meet with ISI Group
Meeting to be held in New York on August 5 hosted by ISI Group.
12:59 EDTDGXQuest Diagnostics management to meet with Craig-Hallum
Subscribe for More Information
July 25, 2014
08:32 EDTDGXQuest Diagnostics price target raised to $74 from $68 at Maxim
Subscribe for More Information
July 24, 2014
07:05 EDTDGXQuest Diagnostics narrows 2014 adjusted EPS view to $4.00-$4.10 from $3.95-$4.15
Subscribe for More Information
07:02 EDTDGXQuest Diagnostics reports Q2 adjusted EPS $1.08, consensus $1.06
Subscribe for More Information
July 22, 2014
07:08 EDTDGXLife Sciences highlights this week at Canaccord
Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use